Last reviewed · How we verify
Hokunalin (tulobuterol) tape
Tulobuterol is a beta-2 adrenergic agonist that stimulates beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.
Tulobuterol is a beta-2 adrenergic agonist that stimulates beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. Used for Asthma, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Hokunalin (tulobuterol) tape |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Beta-2 adrenergic agonist (long-acting) |
| Target | Beta-2 adrenergic receptor (ADRB2) |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Tulobuterol binds to and activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP levels. This leads to smooth muscle relaxation and bronchodilation, improving airway patency and reducing airway resistance. The transdermal tape formulation (Hokunalin) provides sustained delivery over 24 hours for chronic asthma and COPD management.
Approved indications
- Asthma
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Headache
- Palpitations
- Nervousness
- Skin irritation at application site
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hokunalin (tulobuterol) tape CI brief — competitive landscape report
- Hokunalin (tulobuterol) tape updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI